Cargando…
Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
BACKGROUND: Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome....
Autores principales: | Wang, Keshan, Ruan, Hailong, Xu, Tianbo, Liu, Lei, Liu, Di, Yang, Hongmei, Zhang, Xiaoping, Chen, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983013/ https://www.ncbi.nlm.nih.gov/pubmed/29881290 http://dx.doi.org/10.2147/OTT.S159777 |
Ejemplares similares
-
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
por: Yin, Lina, et al.
Publicado: (2013) -
RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma
por: Liu, Yuenan, et al.
Publicado: (2019) -
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
por: Di Nunno, Vincenzo, et al.
Publicado: (2018) -
Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma
por: Cao, Qi, et al.
Publicado: (2018) -
ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
por: Xu, Tianbo, et al.
Publicado: (2020)